deltatrials
Terminated PHASE4 INTERVENTIONAL 2-arm NCT04614233

Targeting the Gut-brain Axis to Facilitate Weight Loss in High Fat Diet Consumers

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions Overweight and Obesity
Interventions Placebo RiduZone (90% OEA)
Updated 14 times since 2020 Last updated: Jan 8, 2025 Started: Apr 6, 2021 Primary completion: Oct 4, 2024 Completion: Oct 4, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

PI changed institutions

Other terminated trials from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

See all terminations from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Other Overweight and Obesity trials with similar outcome

Browse all Overweight and Obesity trials

Listed as NCT04614233, this PHASE4 trial focuses on Overweight and Obesity and remains terminated or withdrawn. Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), it has been updated 14 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jul 2023 · 7 months · monthly snapshot~Jul 2023 – ~Dec 2023 · 5 months · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – present · 17 months · monthly snapshot

Change History

14 versions recorded

  1. Feb 2025 — Present [monthly]

    Terminated PHASE4

    Status: Active Not Recruiting → Terminated

  2. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE4

  4. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE4

  5. Jan 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE4

▶ Show 9 earlier versions

  1. Dec 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  2. Jul 2023 — Dec 2023 [monthly]

    Recruiting PHASE4

    Phase: PHASE3 → PHASE4

  3. Dec 2022 — Jul 2023 [monthly]

    Recruiting PHASE3

    Phase: PHASE4 → PHASE3

  4. Dec 2021 — Dec 2022 [monthly]

    Recruiting PHASE4

  5. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE4

  6. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE4

  7. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  8. Jan 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE4

  9. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Yale University
Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations